% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

biotechbeagle 153 posts  |  Last Activity: 13 hours ago Member since: Feb 11, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    "Small Bio-Tech Ready To Explode"

    by ambs_advocate Aug 28, 2015 4:40 PM
    biotechbeagle biotechbeagle 13 hours ago Flag

    You've found the wrong message board my friend!

  • Reply to

    any takers?

    by cchrag Aug 20, 2015 4:49 PM
    biotechbeagle biotechbeagle Aug 20, 2015 11:21 PM Flag

    Baker Brothers appear to be takers as they have purchased another 1.3 million shares upping their stake to 2.3 million shares

  • biotechbeagle by biotechbeagle Aug 19, 2015 8:28 AM Flag

    Cardica ( CRDC ) (reports Aug. 6, after the market close) continues to face a challenging road as it attempts to improve the performance of its MicroCutter XCHANGE 30 stapler; while there are still several concerns that need to be considered, we believe Cardica has been inching its way in the right direction and remain cautiously optimistic of a year-end relaunch of its XCHANGE 30, for both white and blue cartridges. We expect the stapler could be in clinical evaluation by the end of the calendar third quarter/early fourth quarter timeframe. In the international markets, Cardica initiated a controlled/limited European launch of the XCHANGE 30 (white cartridge only) at the end of March, primarily in the U.K. and Germany; the company filed for 510(k) clearance for a vascular indication at the end of April.

    Cardica (NASDAQ:CRDC) had its target price decreased by Wedbush from $1.75 to $1.50in a report published on Friday morning. Wedbush currently has an outperform rating on the stock.

  • Cardica, a designer and manufacturer of proprietary stapling and automated anastomotic devices for cardiac and laparoscopic surgical procedures, has partnered with precision laser-cutting and engineering firm, A-Laser, to expand and refine its line of next-generation medical devices.

    "For several years, we have worked with A-Laser on a number of product prototypes as well as ongoing precision parts manufacturing," explains Donovan Ware, Materials Manager for Redwood City, California-based Cardica. "The quality of the laser-cut components A-Laser supplies is consistently high and the engineering team continues to be an invaluable resource for ensuring proper materials sourcing and design collaboration."

    Cardica's relationship with A-Laser began with the development of its revolutionary MicroCutter XCHANGE® 30 surgical stapler, an 80° articulating device with an exceptionally small 5mm shaft. Precision laser cutting of thin metal parts with tight tolerances was critical for the prototype development of this product and A-Laser's comprehensive range of laser cutting services and the company's engineering expertise have been instrumental in the progression of the MicroCutter product line.

    "Our partnership with Cardica is very rewarding," comments Josh Saunders, A-Laser's President. "Knowing that we are playing a part in the manufacture of revolutionary medical devices is gratifying. And, the challenging designs from Cardica drive us to innovate new ways to manufacture exceptionally small, precise stainless steel components. In fact, one part can only be manufactured through a process of chemical etching and laser cutting, which is a technique A-Laser perfected and now employs to produce a specialty part used in Cardica's MicroCutter device.

  • Reply to

    General biotech and pharma drop today

    by defilip1 Aug 6, 2015 3:04 PM
    biotechbeagle biotechbeagle Aug 11, 2015 12:32 PM Flag

    Think it's a safe bet as your right on the 200 day SMA. Looks like this is were the support level is.

  • biotechbeagle biotechbeagle Aug 5, 2015 7:16 AM Flag

    Buyout rumors really? Didn't see that anywhere. Where did you hear that?

  • Cantor Fitzgerald downgraded Immunogen Inc. (NASDAQ: IMGN) from Buy to Hold with a price target of $21.00 (from $12.00) on valuation.

    Analyst Mara Goldstein commented, "We are downgrading ImmunoGen shares to HOLD from BUY, and raising our PT to $21 from $12. Our PT raise reflects greater value for IMGN853, about to enter Phase II, and the remainder of the pipeline. However, we feel that these assets are fairly well represented in our new valuation, and while the shares still have room to advance, the upside is less than what we typically like to see for BUY-rated biotechs. We think there is incremental upside to be had from the pipeline, but major inflection points are not likely, in our view, before 2H:CY16."

  • Reply to

    Enta earnings....

    by biotechbeagle Aug 2, 2015 10:45 AM
    biotechbeagle biotechbeagle Aug 3, 2015 12:42 PM Flag

    The ABBV bad news was out and we dropped $4+ and then rebounded strongly the next day! So bad news out and we are looking to make a new 52 week high. Seems very bullish for a long term hold. Thoughts?

  • biotechbeagle by biotechbeagle Aug 2, 2015 10:45 AM Flag

    What's everyone think about earnings? ABBV Hep c revenue exceed expectations by $15million for the qtr however, the underlying scripts did not meet. Does this matter for ENTA? Barrons said the buy point for the stock was $51.00. We achieved that, so it should go higher. Data for ABT 493 should be coming out 2H 2015 as well as preclinical candidate selection for NASH. So will there be a short term pull back or will earnings exceed and drive greater momentum? Believe this stock is header higher and something big may be going on behind the seen as the buy interest has been very strong!

    Sentiment: Buy

  • Reply to

    ETFs buying 5 -10% of ENTA?

    by bwoo_ny Jul 28, 2015 1:46 PM
    biotechbeagle biotechbeagle Jul 28, 2015 4:08 PM Flag

    Think so, did you see the after hours block of 808,000 and 54,000?

  • Reply to

    Q2 ABBV Viekira Pak number

    by gardener7james Jul 24, 2015 9:59 AM
    biotechbeagle biotechbeagle Jul 24, 2015 2:43 PM Flag

    Why are we down when Abbv exceeded Q2 expectations on Viekira Pak?

  • All gains have been on larger than normal volume. Low liquidity creates exaggerated swings here.

  • Reply to

    IMGN 853

    by cchrag Jul 20, 2015 10:13 AM
    biotechbeagle biotechbeagle Jul 20, 2015 12:15 PM Flag

    Are you saying the FDA should ignore 53% response to an unmet medical need just because others have failed? Others have failed with immunotherapy targeting Car T in the past so should these new breakthrough therapies be eliminated as well? Don't let your short position get in the way of a much needed therapy to those suffering from platinum resistant ovarian cancer.

  • Reply to

    Could this be the reason for big move?

    by biotechbeagle Jul 17, 2015 9:45 PM
    biotechbeagle biotechbeagle Jul 17, 2015 9:53 PM Flag

    Drugs like IMGN 853 are the benefactors of this policy. Although IMGN 853 may also qualify for Breakthrough Therapy Designation.

    Qualifying Criteria for Breakthrough Therapy Designation
    Breakthrough therapy designation applies to the drug (either alone or in combination with other
    drugs) and the specific use for which it is being studied. The term drug refers to the combination
    of two or more drugs if the combination is the subject of the breakthrough therapy designation or
    request. Where appropriate, FDA may grant designation to the development of a new use of an
    approved drug.
    1. Serious Condition
    2. Existing (or Available) Therapies
    3. Preliminary Clinical Evidence
    4. May Demonstrate Substantial Improvement on Clinically Significant Endpoint(s)
    Features of Breakthrough Therapy Designation
    1. Intensive Guidance on an Efficient Drug Development Program, Beginning as
    Early as Phase 1
    2. Organizational Commitment Involving Senior Managers
    3. Submission of Portions of an Application (Rolling Review)

  • On Friday, July 10th the U.S. House voted overwhelmingly to streamline the approval process of prescription drugs and medical devices by the FDA. If passed in the Senate and signed by President Obama, the “21st Century Cures Act” (the “Act”) would foster significant regulatory changes in the introduction of new drugs to the market. The legislation passed 344-77 with strong, bipartisan support, though opponents raise concerns about the Act’s lack of assurances of patient safety.

    The main focus of the 352-page Act is a reduction of bottlenecks in the regulatory process that, supporters claim, slow the development of new drugs. The Act would trim regulations by allowing for shorter clinical studies involving fewer individuals for certain kinds of drugs. It would also allow for expanded use of surrogate endpoints as evidence of the efficacy of drugs. Surrogate endpoints are biomarkers (such as blood pressure for hypertension), which are thought to predict clinical benefit, but are not outright measures of such benefit. Use of surrogate endpoints can significantly decrease the time of clinical trials. For example, instead of having to wait to learn if a drug actually extends survival for diabetic patients, the FDA could approve a drug based on evidence that it reduces hemoglobin A1C levels. The onus remains on drug makers to then prove that reductions in A1C levels lead to a longer lifespan.

    If a drug that is already on the market is shown to have a new use, the Act will allow case studies to suffice as evidence of the new benefit rather than require additional clinical trials. The Act will also increase the use of patient registries and existing health care data to speed up clinical trials. These regulatory changes would be enhanced by a five-year, $8.75 billion increase in funding to the National Institutes of Health – a major financier of biomedical research in the U.S. The NIH would also host a new Cures Innovation Fund which would support breakthrough biomedical research. The Act would enhance funding to the FDA by $550 million.

    Sentiment: Buy

  • Barrron's says $52 would be the buy point!

  • biotechbeagle biotechbeagle Jul 16, 2015 2:09 PM Flag

    So for you option traders, does this mean today starts the short squeeze and we may have up to 8 trading days to enjoy new highs?

    IMGN has skyrocketed 14.7% to sit at $16.54, and earlier notched an annual high of $16.63, despite the lack of a clear driver. The stock's 30-day at-the-money implied volatility has soared 16.1% to 68.6% -- in the 79th percentile of its annual range -- and calls are running at twice the average afternoon clip, with bullish buy-to-open action spotted at the July 16 call.

    As with OHRP, today's affinity for long calls marks a change of pace for IMGN. On the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the stock's 50-day put/call volume ratio of 0.36 stands higher than 77% of all other readings from the past 12 months. Likewise, the equity's SOIR of 0.95 registers in the 89th percentile of its annual range.

    A short squeeze could add fuel to ImmunoGen, Inc.'s fire, though. Short interest accounts for 13.7% of the stock's total available float, representing nearly eight sessions' worth of pent-up buying demand, at the equity's average pace of trading.

  • Reply to

    Why is ENTA so volatile?

    by defilip1 Jun 25, 2015 8:42 AM
    biotechbeagle biotechbeagle Jun 26, 2015 7:06 PM Flag

    Low liquidity. It had to pull back sometime, it's been on a meteroric rise. This is healthy for next move up. Luly sounded very positive and excited about what they have going on during the JPM conference

  • biotechbeagle biotechbeagle Jun 21, 2015 4:42 PM Flag

    Only other reason would be because he's leaving company and would lose them. Either way it is positive!

  • Reply to

    Nice move! What's going on?

    by biotechbeagle Jun 15, 2015 4:01 PM
    biotechbeagle biotechbeagle Jun 19, 2015 4:51 PM Flag

    My error, 200,000 share buy block which is large for Enta

12.98-0.48(-3.57%)Sep 1 4:00 PMEDT